Skip to content
AGI Future Foundation PBC

W3 LLC · Series S04 · Intended / Planned

Curable.X

Curative and treatment-focused work — a planned domain, with almost nothing verified beyond the name.

Read the statusGet involved

S04series number in the April 2026 internal list
Plannednot formed, not funded, not offered
No anchor yetno anchored metaverse fabric yet

Source for the name and number: the April 2026 internal W3 series list (internal printout, dated 2026-04-03, not a Wyoming Secretary of State filing). The list names 33 sub-series, Series 1–33. It proves no filing, no legal designation, no bank account, no EIN, and no Steward Council per series.

What this series is

Curable.X is Series 4 in the April 2026 internal W3 series list. That sentence, together with the name itself, is very nearly everything verified that can be said about this series. Its name implies a focus on cures and curative treatment — on making people better, not only on diagnosing what is wrong with them — and this page describes that as a planned focus, because no product, condition, therapy, research programme, partner, clinician, trial, or publication for Curable.X is verified in the files. This is a thin page on purpose: where there is almost nothing verified to say, the honest page says so plainly instead of filling the space with invention.

The domain the name implies is worth sketching carefully, because the sketch itself shows how much is still undefined. “Curable” could point at many different kinds of work: developing a treatment for a specific condition, improving how existing treatments are chosen or delivered, supporting recovery and rehabilitation, or building tools that help clinicians and patients track whether a treatment is working. Each of those is a different venture, with different expertise, different regulation, and different risks, and no verified document says which of them Curable.X intends. The name alone does not choose between them, and this page does not choose on the series’ behalf.

What can be said without inventing anything is what a curative series would have to get right if it were built. A treatment claim is a claim about a human body, so it would need evidence: what condition, what intervention, what outcome, measured how, in whom, and with what risks. It would need to be clear about the line between supporting treatment decisions and making them, and about who — a named human clinician, not an agent — bears responsibility for a decision about a patient. It would need to say what it does not do, as clearly as what it does. None of those statements exists for Curable.X today, and their absence is not a gap to be papered over with confident language; it is the current state of the series, and it is stated here as such.

There is one neighbouring fact that needs to be handled explicitly, because it could easily confuse a reader. The internal list also contains a Series 17 named Curable.Blockchain DAO. No verified document explains the relationship between Curable.X (Series 4) and Curable.Blockchain DAO (Series 17) — whether they are two views of one effort, two separate efforts in the same domain, or a naming overlap that was never resolved. This page does not merge them, does not assign Series 17’s implied blockchain focus to this series, and does not claim any shared work between them. If the relationship is ever defined in writing, this page should be updated to say what it is and cite the document. Until then, the two names stand side by side in the list, unexplained.

Metaverse connection

No anchored metaverse fabric yet. Curable.X has no verified anchored world: no coordinates, no fabric JSON, and no metaverse location are recorded for this series in the materials reviewed. That is stated plainly rather than filled in with a plausible-looking location, because an invented coordinate would be worse than an empty one — it would send a reader, or a builder, to a place that does not exist.

What would be needed for a metaverse presence is the same sequence that the anchored series went through, and it has not started for Curable.X: a decision about what a world for this series would be for, a fabric definition published at a checkable address, the assets that fabric references hosted at the paths it expects, and a verified render in Artemis. After that, a live metaverse-server endpoint would be needed before anything could be attached on RP1 — and zero worlds are live on RP1 today, for any series, so there is no RP1 presence to describe for this one either. A metaverse world for a treatment-focused series would also need its own safety thinking before it existed: a world that discussed treatment would have to be clear, in the world itself, that it is not a clinic and does not treat anyone. No such design exists, so none is claimed.

What exists today — and what is planned

What exists today

One thing is verified: the name and number — Curable.X, Series 4, in the April 2026 internal W3 series list. No product, condition, therapy, trial, partner, clinician, publication, or metaverse fabric is verified for this series. That is the complete verified inventory, and it is short.

What is planned

Everything else is planned, not existing: the formation of W3 LLC and the designation of this series; a human Steward Council and operating rules; a defined scope (which conditions, which treatments, which kind of work); any evidence, validation, or clinical relationship; any funding; and any metaverse presence. Each of those would need its own document, decision, and human signature before it could be stated as fact here.

The most useful next step for Curable.X would be the smallest one that adds real information: a written statement of scope from a named human steward, saying which kind of curative work the series intends and which kinds it explicitly does not. Until that document exists, this page will remain thin, and that thinness is the accurate record — not a draft to be padded, but a faithful account of a series that is currently a name and a planned domain.

How it fits — tier, related series, and governance

The intended structure, in words. At the top of the intended structure sits the AGI Future Foundation, a filed California nonprofit public benefit corporation (Entity No. B20260196664, Articles filed 2026-04-24, EIN assigned 2026-05-07). Below it, in the intended plan, sits W3 LLC, a Wyoming series LLC, and below that the individual series — of which Curable.X is S04 in the April 2026 internal list. That is the plan as described in the Foundation’s own materials. It is not a description of a completed legal structure: W3 LLC formation and per-series designation are not verified in filings, so the middle and bottom tiers of that diagram are intended, not established. Nothing on this page should be read as saying the Foundation owns, controls, or has formed Curable.X, or that Curable.X exists as a company, a fund, or an operating business today.

Related series. The series that sit closest to Curable.X by subject matter are listed in the card below. “Related” here means only that their names point at neighbouring domains. It does not mean that any joint project, shared budget, shared staff, partnership agreement, or data-sharing arrangement exists between them. No such arrangement is verified for Curable.X, and none is claimed here. If two series ever do work together, that would need its own written agreement, its own human approvals, and its own public record — none of which exists yet for this series.

Related series (by domain only)

S03 Diagnostic.X (diagnosis precedes treatment), S05 BioPharma.Go (medicines and therapies), S17 Curable.Blockchain DAO (the blockchain-named counterpart to this series), and S14 AskDoc.X are the nearest neighbours by domain. No joint work is verified with any of them, and the relationship between this series and S17 is not explained in any verified document.

Governance — planned, not yet operating

The planned governance model for the W3 series, as described on the Foundation site, is DAO-managed day-to-day work with human decision-making at every point that matters: agents may draft proposals, prepare research, and operate routine systems, but humans decide, humans sign, and humans move funds. A Steward Council of humans is intended to hold that gate. No Steward Council membership, no signed votes, no seated manager, and no operating agreement for Curable.X is verified in the files, so none is named here. Until those human roles are seated in writing, there is no one who can speak for, commit, or spend on behalf of this series — and this page does not do so.

What governance would have to answer first. Before Curable.X could do substantive work, its human stewards would need to settle, in writing, at least these questions: what exactly is in scope and what is out of scope; who the stewards are and how they are replaced; what agents may and may not do without a human signature; how money, if any ever exists, is held, accounted for, and reported; and how the series relates to the Foundation’s public-benefit purpose. None of those answers exists in a verified document today. Listing the questions is not the same as answering them, and this page deliberately does not pretend otherwise.

What would have to happen before this series could operate

A named series is not a formed series. For Curable.X to move from a line in an internal list to an operating venture, several distinct steps would each have to happen, in order, with documents to prove them. First, W3 LLC itself would need to be formed and evidenced by a filing that can be checked. Second, this series would need to be designated in writing as a series of that LLC, with its own name, purpose, and manager recorded. Third, the series would need its own operating rules, its own human stewards, and its own segregated accounting — so that its money, liabilities, and records are not mixed with any other series or with the Foundation. Fourth, any bank account, contract, hire, or public claim would need a named human signer acting under those written rules. Fifth, any fundraising would need its own counsel-approved documents, its own issuer, and its own securities compliance — it could not borrow the Foundation’s nonprofit status, and the Foundation, as filed, cannot offer equity or a SAFE. None of those steps is verified as done for Curable.X. This section is included so that a reader can see the gap plainly, rather than mistaking a polished landing page for a finished company.

That gap is also why this page carries no timeline. There is no launch date, no funding date, and no hiring date stated here, because none has been set in a verified document. A date on a landing page would look like a commitment; without a filing, a budget, and a human team behind it, it would be a decoration, not a plan. When a real date exists, it should appear here with the document behind it cited.

Proposed projects — for DAO review

These are proposals for the series DAO team to review. None is approved, funded, staffed, or scheduled.

Almost nothing is verified about this series beyond its name and its number in the April 2026 internal W3 series list. The name implies a focus on cures and curative treatment, on making people better rather than only diagnosing what is wrong. The proposals below are generic to that name-implied planned focus, and no product, condition, therapy, research programme, partner, clinician, trial, or publication is verified for this series.

Scope definition paper

A one-page written statement of what curative means for this series: which kinds of treatment work are in scope, which are out of scope, and what the series will not claim. The paper would be the first document stewards approve before any research begins. No such paper exists today.

What success would look like: A scope paper exists that the stewards have approved, stating in one page what curative means here.

Reviewing team: the Curable.X DAO

Status: PROPOSED — pending DAO team review

No funding, partner, or timeline yet.

Condition prioritisation framework

A proposal for how this series would choose which conditions to focus on, with stated criteria such as unmet need, feasibility, and safety. The framework would be a decision tool for stewards, not a promise about any condition. No such framework exists today.

What success would look like: A framework exists with written criteria that stewards can apply to any candidate condition.

Reviewing team: the Curable.X DAO

Status: PROPOSED — pending DAO team review

No funding, partner, or timeline yet.

Clinician partnership principles

Written principles for any future collaboration with clinicians, covering who decides treatment questions, how evidence is weighed, and how patients are protected. The principles would be agreed before any partnership is sought. No clinician partner is verified for this series.

What success would look like: A principles draft exists that a named clinician has reviewed for real-world sense.

Reviewing team: the Curable.X DAO

Status: PROPOSED — pending DAO team review

No funding, partner, or timeline yet.

Treatment evidence standard

A proposal that any treatment claim from this series state its evidence plainly: what was shown, in whom, and with what limits. The standard would keep the series from overstating early results. No such standard exists today.

What success would look like: An evidence standard exists with a template that every treatment claim must complete before it is shared.

Reviewing team: the Curable.X DAO

Status: PROPOSED — pending DAO team review

No funding, partner, or timeline yet.

Patient safety first paper

A written set of safety commitments that would come before any curative work: do no harm, human oversight of every treatment decision, and honest reporting of setbacks. The paper would be approved by stewards before any programme starts. No such paper exists today.

What success would look like: A safety paper exists that the stewards have approved, with commitments that bind any future curative work.

Reviewing team: the Curable.X DAO

Status: PROPOSED — pending DAO team review

No funding, partner, or timeline yet.

Code and repositories

No dedicated repository for this series was found in the audit (Foundation llms.txt). Two generated agent files touch it, neither read in full in this pass. In agi-corp-worlds, agents/prompts/s04-curable-x.json is one of the roughly 40 generated prompt files from the metaprompt system, and its spec metaprompt is marked not ready in the prompt index: the founder focus for this series is unset, labelled “awaiting a founder focus” and never filled with a guess. In WorldForge-Browser, a per-series tutor prompt, worldforge/out/training/tutors/s04-curable-x.md, was identified in the org sweep; its contents have not been read, so nothing about it is described here. An Omega liaison card for this series is listed in the s04–s35 range of the 38 agent cards in Metropolis-SmartCiti (agents/cards/); its contents were not individually read. See the organisation on GitHub: AGIFutureFoundation.

Visit in VR

There is no flagship 3D world for Curable.X, and no playable world exists for this series yet. What exists is an index listing: the series appears as a curated entry (s04-curable-x) in the worlds-3d 544-world index, and a series directory (worlds/s04-curable-x/) exists in agi-corp-worlds. Its founder focus is unset in that repo’s focus sheet — labelled “awaiting a founder focus”, never filled with a guess — and its spec metaprompt is marked not ready in the prompt index.

Zero worlds are live on RP1, and the lobby labels itself a web 3D interpretation — not RP1, not footage. A world for this series becomes real only when a steward writes its focus into the focus sheet.

The biology in depth

Abstract illustration of a branching pathway of light forking across a dark field
AI-generated illustration

Curative medicine is the part of medicine that aims to cure disease rather than manage its symptoms: a treatment that removes the cause, repairs the damage, or restores the body to health, so the disease does not return. That is a research direction, not a shelf of finished cures. Most diseases studied today have no curative treatment, and the work of finding one runs through laboratory biology, animal and cell models, staged human trials, safety review, and regulation — each step able to stop a candidate that looked promising at the step before. A series named for cures therefore has to be judged on the quality of its research questions and its willingness to report negative results, not on how many cures it claims.

Longevity belongs in the same frame. Research into healthy ageing — why bodies decline with age, and whether that decline can be slowed or partly reversed — is a live research direction with open questions and no settled answers. This page makes no claim about any longevity outcome, therapy, or timeline, because none is verified for this series. Any future longevity work under this name would have to be presented as research, with its evidence and its limits stated together.

What is verified for this series is thin, and this section says so plainly. Curable.X is S4, named in the April 2026 internal W3 series list. A name search over all 90 public repositories in the Foundation account, checked 2026-11-06/07, found no repository for this series — no code, no dataset, no tool, no trial record. No trial, result, partnership, or timeline is verified for Curable.X, and none is claimed here. The planned work — a written mission naming the diseases or mechanisms in scope, a Steward Council, and a research design reviewed by qualified humans with ethics review and counsel — is described in the sections above as planned, not existing.

The nearest neighbours are the other health series: S5 BioPharma.Go, where a future therapy would be developed and made; S11 Molecular, where its mechanism would be studied at molecular level; S17 Curable.Blockchain DAO, the neighbouring blockchain DAO in health; and S18 BioDAO.blockchain DAO, where biological data would be recorded. None of those relationships is a partnership today. Each is a conversation and a written agreement for the future, if the series involved become active.

All verified BioDAO tools are listed together, with charts, on the BioDAO tools page.

Get involved / contact

If you are interested in Curable.X, the route is a conversation, not a transaction. Write to [email protected] and say who you are, what your interest is, and what you could contribute — research, building, review, or simply following the work. A reply, if one comes, will come from a human. Agents writing in should follow the same route the Foundation sets out on its home page: state your operator and your human principal, and do not present yourself as the Foundation or commit it to anything.

What this page is not. This page is not an offer to sell securities, not an invitation to invest, and not a solicitation of funds for this series. There are no investment terms here — no price, no valuation, no cap, no discount, no minimum, no return, and no deadline — because there is nothing to invest in yet: the series is not formed, not funded, and not offered. No suggested valuation is assigned to Curable.X on this page, and none should be inferred from valuations discussed elsewhere for other entities; those figures, where they exist, are illustrative planning figures for different issuers and do not transfer to this series. If you are considering any payment to any entity in this family, ask first for the filing, the determination letter if tax treatment matters to you, and the counsel-approved offering documents — and take independent legal and tax advice before acting.

Nothing on this page is legal, tax, or financial advice. Filed facts stated here are: AGI Future Foundation, California Nonprofit Public Benefit Corporation, Entity No. B20260196664, Articles filed 2026-04-24, EIN assigned 2026-05-07; no IRS 501(c)(3) determination letter in the files, so no tax-exempt status or tax-deductible donations are claimed. AGI Corp has an EIN only (assigned 2026-05-16); its incorporation is unverified. The live Foundation site lists a “66-W3 Wyoming Series network” and “33 agentic subsidiaries” — that numbering is site copy, not a filing, and it sits alongside the 33 named sub-series in the April 2026 internal list.

← All 33 series Foundation home